Amendments to the Claims:

Please amend the claims as follows:

1. (Original) An immunogenic composition comprising an isolated transferrin binding protein (Tbp) or antigenic fragment thereof and an isolated Hsf like protein or antigenic fragment thereof from the same or different Gram negative bacteria.

2. (Original) The immunogenic composition of claim 1 in which the transferrin binding protein or fragment thereof and Hsf like protein or fragment thereof are from Neisseria.

3. (Previously Presented) The immunogenic composition of claim 1 in which the transferrin binding protein or fragment thereof is derived from *N. meningitidis.*

4. (Previously Presented) The immunogenic composition of claim 1 in which the Hsf like protein or fragment thereof is derived from *N. meningitidis.*

5. (Previously Presented) The immunogenic composition of claim 1 in which the transferrin binding protein or fragment thereof is derived from *N. meningitidis* serogroup B.

6. (Previously Presented) The immunogenic composition of claim 1 in which the Hsf like protein or fragment thereof is derived from *N. meningitidis* serogroup B.

7. (Previously presented) The immunogenic composition of claim 1 in which the transferrin binding protein or fragment thereof is derived from *N. gonorrhoeae.*

8. (Previously Presented) The immunogenic composition of claim 1 in which the Hsf like protein or antigenic fragment thereof is derived from *N. gonorrhoeae.*

9. (Withdrawn) The immunogenic composition of claim 1 in which the transferrin binding protein or antigenic fragment thereof is derived from *Moraxella catarrhalis.*

10. (Withdrawn) The immunogenic composition of claim 1 in which the Hsf like protein or antigenic fragment thereof is derived from *Moraxella catarrhalis.*

11. (Withdrawn) The immunogenic composition of claim 1 in which the transferrin binding protein or antigenic fragment thereof is derived from *Haemophilus influenzae*.

12. (Withdrawn) The immunogenic composition of claim 1 in which the Hsf like protein or antigenic fragment thereof is derived from *Haemophilus influenzae*.

13. (Previously Presented) The immunogenic composition of claim 1 in which the transferrin binding protein is TbpA or an antigenic fragment thereof.

14. (Original) The immunogenic composition of claim 13 comprising high molecular weight form TbpA or low molecular weight form TbpA or both high molecular weight form TbpA and low molecular weight form TbpA.

15. (Previously Presented) The immunogenic composition of claim 1 in which the Hsf like protein is Hsf or an antigenic fragment thereof.

16. (Previously Presented) The immunogenic composition of claim 1 comprising antigenic fragments of Tbp and/or Hsf like protein capable of generating a protective response against Neisserial, *Moraxella catarrhalis* or *Haemophilus influenzae* infection.

17. (Original) The immunogenic composition of claim 16 comprising antigenic fragments of TbpA and/or Hsf.

18. (Previously Presented) The immunogenic composition of claim 1 comprising a fusion protein of Tbp and Hsf like protein or antigenic fragments thereof.

19. (Original) The immunogenic composition of claim 18 comprising a fusion protein comprising TbpA and Hsf or antigenic fragments thereof capable of generating a protective response against Neisserial infection.

20. (Withdrawn) An isolated immunogenic composition comprising an outer membrane vesicle preparation derived from Gram negative bacteria, in which expression of both

transferrin binding protein and Hsf like protein are at least 1.5 fold higher than naturally occurring in the unmodified Gram negative bacteria.

21. (Withdrawn) The immunogenic composition of claim 20 in which the expression of transferrin binding protein is upregulated by growth under iron limitation conditions.

22. (Withdrawn) The immunogenic composition of claim 20 in which at least a part of the outer membrane vesicle preparation is derived from Neisseria.

23. (Withdrawn The immunogenic composition of claim 20 in which at least a part of the outer membrane vesicle preparation is derived from *Neisseria meningitidis*.

24. (Withdrawn) The immunogenic composition of claim 20 in which at least a part of the outer membrane vesicle preparation is derived from *Neisseria meningitidis* serogroup B.

25. (Withdrawn) The immunogenic composition of claim 20 in which at least a part of the outer membrane vesicle preparation is derived from *Neisseria gonorrhoeae*.

26. (Withdrawn) The immunogenic composition of claim 20 wherein a host cell from which the outer membrane vesicle preparation is derived has been engineered so as to down-regulate the expression of one or more of LgtB and LgtE.

27. (Withdrawn) The immunogenic composition of claim 20 wherein a host cell from which the outer membrane vesicle preparation is derived is unable to synthesise capsular polysaccharides and has preferably been engineered so as to down-regulate the expression of and preferably to delete one or more of siaD, ctrA, ctrB, ctrC, ctrD, synA (equivalent to synX and siaA), synB (equivalent to siaB and synC (equivalent to siaC).

28. (Withdrawn) The immunogenic composition of claim 20 wherein a host cell from which the outer membrane vesicle preparation is derived has been engineered so as to down-regulate the expression of and preferably delete one or more of OpC, OpA and PorA.

29. (Withdrawn) The immunogenic composition of claim 20 wherein a host cell from which the outer membrane vesicle preparation is derived has been engineered so as to down-regulate the expression of FrpB.

30. (Withdrawn) The immunogenic composition of claim 20 wherein a host cell from which the outer membrane vesicle preparation is derived has been engineered so as to down-regulate the expression of msbB or HtrB.

31. (Withdrawn) The immunogenic composition of claim 20 wherein the outer membrane vesicle preparation contains LPS which is conjugated to an outer membrane protein (OMP).

32. (Withdrawn) The immunogenic composition of claim 31 wherein LPS is conjugated (preferably intra-bleb) to OMP in situ in the outer membrane vesicle preparation.

33. (Withdrawn) The immunogenic composition of claim 20 in which at least a part of the outer membrane vesicle preparation is derived from *Moraxella catarrhalis*.

34. (Withdrawn) The immunogenic composition of claim 20 in which at least a part of the outer membrane vesicle preparation is derived from *Haemophilus influenzae*.

35. (Withdrawn) The immunogenic composition of claim 20 comprising an outer membrane vesicle preparation isolated from two or more strains of Gram negative bacteria.

36. (Withdrawn) The immunogenic composition of claim 35 in which transferrin binding protein and Hsf like protein are upregulated on different vesicles originating from different bacterial strains or on the same vesicles originating from the same bacterial strain.

37. (Withdrawn) The immunogenic preparation of claim 20 comprising an outer membrane vesicle preparation in which enhanced transferrin binding protein expression is derived from a polynucleic acid introduced into the Gram negative bacteria.

38. (Withdrawn) The immunogenic composition of claim 20 comprising an outer membrane vesicle preparation in which enhanced Hsf like protein expression is derived from a polynucleic acid introduced into the Gram negative bacteria.

39. (Withdrawn) The immunogenic composition of claim 20 comprising an outer membrane vesicle preparation in which enhanced transferrin binding protein and Hsf like protein expression is derived from a polynucleic acid encoding both proteins which was introduced into the Gram negative bacteria.

40. (Withdrawn) The immunogenic composition of claim 20 in which a bacterial strain has been genetically engineered so as to introduce a stronger promoter sequence upstream of a gene encoding transferrin binding protein.

41. (Withdrawn) The immunogenic composition of claim 20 in which a bacterial strain has been genetically engineered so as to introduce a stronger promoter sequence upstream of a gene encoding Hsf like protein.

42. (Withdrawn) The immunogenic composition of claim 20 in which a bacterial strain has been genetically engineered so as to introduce a stronger promoter sequence upstream of genes encoding transferrin binding protein and Hsf like protein.

43. (Withdrawn) The immunogenic composition of claim 20 in which the transferrin binding protein is TbpA which is high molecular weight TbpA, low molecular weight TbpA or both high molecular weight TbpA and low molecular weight TbpA from *N. meningitidis*.

44. (Withdrawn) The immunogenic composition of claim 20 in which the Hsf like protein is Hsf from *Neisseria meningitidis*.

45. (Previously Presented) The immunogenic composition of claim 1 further comprising plain or conjugated bacterial capsular polysaccharide or oligosaccharide.

46. (Previously Presented) The immunogenic composition of claim 1 comprising two or more bacterial capsular polysaccharides or oligosaccharides conjugated to transferrin binding protein or Hsf like proteins or both.

47. (Previously Presented) The immunogenic composition of claim 45 wherein the capsular polysaccharide or oligosaccharide is derived from one or more bacteria selected from the group consisting of *Neisseria meningitidis* serogroup A, *Neisseria meningitidis* serogroup C, *Neisseria meningitidis* serogroup Y, *Neisseria meningitidis* serogroup W-135, *Haemophilus influenzae* b, *Streptococcus pneumoniae*, Group A Streptococci, Group B Streptococci, *Staphylococcus aureus* and *Staphylococcus epidermidis*.

48-50. (Cancelled)

51. (Previously Presented) The immunogenic composition of claim 1 comprising an adjuvant.

52. (Original) The immunogenic composition of claim 51 comprising aluminium salts.

53. (Previously Presented) The immunogenic composition of claim 51 comprising 3D-MPL.

54. (Original) The immunogenic composition of claim 51 comprising an adjuvant containing CpG.

55. (Previously Presented) A vaccine comprising the immunogenic composition of claim 1 and a pharmaceutically acceptable excipient.

56-71. (Cancelled)